{"id":"W3162733280","doi":"10.1016/j.annonc.2021.04.009","title":"VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"Daiichi-Sankyo; Bayer Fund; Regeneron Pharmaceuticals; Eisai; Sanofi; Clovis Oncology; Genentech; AstraZeneca","keywords":"Medicine; Internal medicine; Vinorelbine; Gemcitabine; Oncology; Cancer; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003450589,0.0008731309,0.001670559,0.0003602022,0.0003998488,0.001359805,0.000944953,0.0009967249,0.009062679],"category_scores_gemma":[0.002023655,0.0003556029,0.00159872,0.0003763251,0.0006668065,0.0009082906,0.0004131404,0.003696054,0.001312935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001109107,"about_ca_system_score_gemma":0.001691435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001349138,"about_ca_topic_score_gemma":0.005095444,"domain_scores_codex":[0.999105,0.0005305631,0.00002789989,0.00008757837,0.00007435161,0.0001745492],"domain_scores_gemma":[0.9990374,0.0003011048,0.000164328,0.0001108718,0.00004977607,0.0003365325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7833202,0.01136213,0.003657408,0.001018821,0.002196296,0.00009907781,0.0001273456,0.006301926,0.009127066,0.001363475,0.01827159,0.1631547],"study_design_scores_gemma":[0.6251046,0.3193872,0.01731951,0.0003202736,0.003128537,0.0003022028,0.0001673725,0.006056909,0.005665536,0.002691579,0.01976661,0.0000897536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9533188,0.009450527,0.001570539,0.002681136,0.0007785558,0.002708816,0.01133456,0.0004489163,0.01770805],"genre_scores_gemma":[0.9656625,0.003134835,0.003631048,0.002499232,0.000292074,0.003072056,0.01039077,0.0001748115,0.0111427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009062679,"threshold_uncertainty_score":0.03031766,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1249766791782127,"score_gpt":0.435912532191295,"score_spread":0.3109358530130822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}